A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Clinical trial NCT01101594 · TERMINATED

Trial details

NCT number: NCT01101594
Sponsor: Gilead Sciences
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2010-07-01
Primary completion: 2013-07-01
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.